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Passive in vivo administration of antibody has been shown to enhance as well as 
dampen  specific immune responses upon subsequent  injection of antigen  (1-3).  In 
addition  to  modulating  specific immune  responses,  immune  complexes have  been 
shown  to  nonspecifically  activate  human  (4,  5),  rabbit  (6),  and  murine  (2,  7) 
lymphocytes. Fc fragments derived from enzymatic cleavage of human immunoglob- 
ulin (Ig)  (2, 8-11) and aggregated human gamma globulin (AHGG) t (2, 12) have also 
been shown to induce human and murine bone marrow-derived (B) lymphocytes to 
proliferate and secrete polyclonal antibody. Moreover, Fc fragments possess the same 
immunoregulatory potential described for immune complexes in that both humoral 
(13,  14) and thymus-derived (T) cell-mediated (15,  16) responses are augmented. The 
underlying feature of lymphocyte activation  by immune  complexes, Fc fragments, 
and AHGG is that they all require the carboxyl terminal portion of the Fc region of 
Ig (17). The active fragment of Fc can be derived by macrophage-dependent enzy- 
matic cleavage of Fc into biologically active 14-19,000 tool wt Fc subfragments  (9, 
11). The studies  in this report demonstrate that  a  synthetic 23-amino acid peptide 
homologous to  335-357  in  Eu  IgGa  (18)  has  the  ability  to nonspecifically activate 
lymphocytes and regulate ongoing immune responses. 
Materials and Methods 
Source of Peripheral Blood Lymphocytes (PBL).  Venous blood was collected  in heparinized 
Vacutainer tubes (Beeton,  Dickinson  & Co.,  Rutherford, N  J)  from healthy adult donors of 
* This is publication 2790 from the Department of Immunology, Scripps Clinic and Research Foun- 
dation, La Jolla California.  Supported in part by Biomedical  Research Support Grant RR0-5514  from the 
U. S. Public Health Service and a grant from the Lilly Research Laboratories. 
:~ Supported in part by grant CA-3064 and Research Career Development Award CA-00765 from the 
National Cancer Institute. 
§ To whom reprint requests should be addressed. 
g Supported in part by grants AI07007, AG00783, and AI15161 from the U. S. Public Health Service. 
Abbreviations used in this paper." AHGG, aggregated human gamma globulin; HPLC, high-performance 
liquid chromatography; PBL, peripheral blood lymphocyte; PFC, plaque-forming cell; NK, natural killer; 
N-tBOC, N-(t-butyloxycarbonyl);  SRBC, sheep erythrocyte; TRF, T cell-replacing factor. 
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both  sexes.  Lymphocytes  were  separated  by  gradient  centrifugation  as  previously  described 
(1t). 
Animals.  Male  mice of the C57BL/6 strain  were obtained  from The Jackson  Laboratory, 
Bar Harbor,  ME. BALB/c mice were obtained frorn Scripps Clinic and Research Foundation, 
La Jolla, CA. All mice were between 8 and  15 wk old when used. 
Solid Phase of Synthesis of lgGz Eu (,335-357).  Starting with N-(t-butyloxycarbonyl) (N-tBOC)- 
cyclopentyl-L-glutamate resin ester,  the appropriate  amino acids  (Aginomoto, Tokyo, Japan; 
Bach-Chem,  Los  Angeles,  CA)  were  added  stepwise  as  their  N-tBOC  derivative  using  the 
standard  Merrifield approach  (19).  However, residues Leu-351  and Pro-352 were added as the 
dipeptide, N-tBO(',- i.-  Leucyl-L-proli  he. 
The debtocked  peptide was  purified  by  gel  filtration on Sephadex  G-25  Fine  (Pharrnacia 
Fine Chemicals,  Piscataway,  NJ)  in 0.2  M  acetic acid,  followed by preparative  reverse-phase 
high-performance liquid chromatography  (HPLC)  on C~,-lipopolysaccharide-1  in  15%  aceto- 
nitrile-0.(/5  M  ammonium  formate,  pH  4.25.  Finally,  the  peptide  was  chromatographed  on 
Sephadex G-50 Fine (Pharmacia  Fine Chemicals)  in 0.2 M  acetic acid, and lyophilized. 
The final product  was homogenous by analytical  reverse-phase HPLC on an Ahex Ultras- 
phere-ODS  column  (Altex  Scientific Inc.,  Berkeley,  CA)  in  acetonitrile-water-trifluoroacetic 
acid, and gave a satisfactory amino acid analysis. The sequence was confirmed by the automated 
Edman method.  Samples used for biological tests were judged free of endotoxin by the limulus 
assay  (20). 
Pzeparation of Fc Fragments.  A  human  IgG1  myeloma prolein  (Fi)  was a  gift from Dr. Hans 
L. Spiegelberg, Research Institute of Scripps Clinic. Fc fragments were obtained by enzymatic 
digestion as previously described  (8). 
Isolation of Peripheral Blood B and T Cells.  PBL suspensions were enriched for B and T  cells by 
the  neuraminidase-treated  sheep  erythrocyte  (SRBC)  rosette  technique  (11).  The  T  cell 
populations  were subjected  to  2,000  rad  (Gamma  Cell  40;  Atomic Energy  of Canada,  Ltd., 
Ottawa, Canada)  before use in the in vitro polyclonal antibody response cultures  (11). 
Depletion of TLympho(1,tes.  T lymphocytes were depleted from murine spleen cell preparations 
by  treatment  with  anti-T  cell  serum  (Microbiological  Associates,  Walkersville,  MD)  and 
complemen~  as described previously (10). 
Enrzchment of T  Lymphocytes.  Murine  spleen  cell  populations  were enriched  for T  cells by 
filtration through nylon wool columns (Fenwal  Laboratories, Morton Grove, IL) (10). 
Depletion of Macrophages.  Spleen  cells  were  filtered  through  columns  of Sephadex  G-10 
(Pharmacia  Fine Chemicals) by the method of Ly and MishelI (2t) as described previously (7, 
8). 
Murine Lymphocyte Response Assays 
PROLIFERATIVE RESPONSV. The Fc fragment-rnediated  proliferative response was carried out 
as previously described  (8). 
POLYCLONAE ANTIBODY RESPONSE. The  Fc fragment-mediated  polyclonal antibody  response 
was carried out as previously described  (10,  22). 
IN VITRO ANTI-SRBC  RESPONSE. Spleen ceils were removed from mice injected intraperitoneally 
4  6  wk previously with 0.1  ml  10% suspension  of SRBC. A  modified Mishell-Dutton  culture 
system was used for the generation of antibody-producing cells (13). 
IN vIvo ANTI-SRBC RESPONSE. Mice were given 0.1  ml 0. I~Y~: suspension  of SRBC intraperito- 
neally,  followed  by  saline  or  Fc  peptide  intravenously.  The  spleens  were  assessed  for  IgM 
plaque-forming cells  (PFC)  to  SRBC  4  d  postimmunization.  Results  are expressed  as  mean 
PFC from spleens of four to five mice plus standard  error of the mean. 
CYTOTOXIC RESPONSE. Mice  were  injected  with  peptide  and  5  d  later  their  spleens  were 
assessed  for the ability  to  lyse the  natural  killer  (NK)-sensitive Yac-1  cell line. Targets were 
prepared  by  labeling  Yac-1  cells with  SlCr  (250  500  mCi/mg;  Amersham  Corp.,  Arlington 
Heights,  IL)  as  previously described  (16).  The  cell mixtures  were  then  incubated  for 4  h  at 
37°C in 5% CO2, and aliquots of cell-free supernatant  were then  taken and  their 51Cr content 
determined. The cytolytic activity was determined by the equation: percent specific release = 
](experimental  SICr  release  -  control  51Cr release)/(maximum  51Cr release  -  control  '~'lCr 
release)I ×  100. Maximum release =  3 ×  freeze thaw. MORGAN  ET  AL.  949 
Human Lymphocyte Response Assays 
POLYCLONAL  AN'rlBOD'~  ~ RESPONSE  TO VC FRAGMENTS.  The protocol used has been described in 
detail previously (1 t). The number of Ig-secreting cells was determined 6 d later by the protein 
A plaque assay (23). 
IN VITRO ANTI-SRBC  RESPONSE. The primary anti-SRBC response was done as described by 
Misiti and Waldmann (24). 5 ×  106 PBL were cultured in 1 ml RPMI 1640 supplemented with 
2 mM L-glutamine, 1% basal medium Eagle vitamins, antibiotics, 5 ×  10  -5 2-mercaptoethanol, 
and the SRBC-absorbed autologous human plasma was substituted for the fetal calf serum. 
ANTIGEN-INDUCED  PROLIFERATIVE  RESPONSE. The proliferative response to tetanus toxoid was 
carried out as described by Broff et  al.  (25).  Briefly,  1 ×  l0  s PBL were cultured with  5 big 
tetanus  toxoid/ml  (Commonwealth of Massachusetts  Dept.  of Public  Health,  Boston), The 
response was assayed on day 8 of culture. 
Results 
In  Vitro Polyclonal Activation by Fc Peptide.  The 23-amino acid synthetic Fc peptide 
shown  in  Fig.  1  was  synthesized  and  assessed  for  biological  activity.  Increasing 
amounts  of Fc peptide  ,were cultured  with  murine  spleen  cells,  and  the  polyclonal 
antibody responses  were measured.  The results  in  Fig.  2  reveal  that  murine  spleen 
cells are stimulated by Fc peptide to secrete polyclonaI antibody in a  dose-dependent 
fashion.  Optimal  stimulation  occurred when  7.5  X  10 -a/~mol peptide/ml  (0.17/Lg/ 
ml) was added;  this response was comparable to that induced by  1 X  10 -3 #tool Fc/ 
ml (I66 #g/ml). Because Fc fragments have also been shown to stimulate human PBL 
to secrete high levels of polyclonal antibody (I 1),  the Fc peptide  was assessed for its 
ability  to  stimulate  polyclonal  antibody  production  by  normal  human  PBL.  The 
addition  of Fc  peptide  to  in  vitro  PBL  cultures  resulted  in  the  induction  of  a 
significant polyclonal antibody response (Table I). The optimal response was achieved 
with  1.3  ×  10  -S #tool  peptide/ml  (0.03  #g/ml).  On  a  mole  per  mole  basis  the  Fc 
peptide is more active in inducing polyclonal antibody production than Fc. In contrast 
to  Fc  fragments,  Fc  peptide  was  unable  to  induce  B  cell  proliferation  (data  not 
shown). 
FIc,  1. 
H~N-Thr-lle-Ser-Lys-Ala-Lys-Gly-GIn-Pro-Arg'(;lu-Pro- 
-GIn-VaI-  Tyr-  Thr-Leu-Pro-Pro-Ser-Aro-Glu-Glu-COOH 
Synthetic Fc peptide based on EU IgGj sequence 335-357. 
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FIe,.  2.  Comparison of the ability of Fc peptide and Fc fragments to induce an in vitro polyclonal 
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TABLE  I 
Ability of a 23-Amino Acid Synthetic  Fc Peptide  to Induce a Polyclonal 
Antibody  Response by Human PBL * 
Stimulator  /mml/ml  Ig-secreting cells/106  B 
cells 4- SE 
--  --  230 4-  2(1 
23 Peptide  1.3 X 10  -~  1,040 4- 7 
1.3 X  10  -e'  1,642 4-  19 
1/3 X  10  -4  450 4- 37 
* Polyclonal antibody response was measured on day 6 of culture. 
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FIG.  3.  Requirement for T  cells in the Fc-peptide-induced xmarine polycfonaI  antibody response. 
Varying ratios of T/B cells were assessed for their ability to make polyctonaI antibody in response 
to Fc peptide stimulation. 7.5 X 10  -r'/mini (0.17 F-g) Fc peptide/ml was used.  Direct anti-TNP PFC 
4- SE were measured. 
The Fc fragment-mediated polyclonal antibody response has been shown to have 
a  strict requirement for accessory T  cells (10,  11, 26)  and macrophages  (10,  1  I). To 
ascertain the role of T  cells in the Fc peptide-induced polyclonal antibody response, 
cell-mixing experiments were performed. Spleen cell populations depleted of T  cells 
were found to be unable to produce polyclonal antibody in  response to Fc peptide 
stimulation (Fig. 3), thus indicating the need for T  cells. Restoration of the polyclonal 
antibody response was accomplished by the addition of nylon wool-purified T  cells to 
culture (Fig. 3). A  mixture of ~50% B cell-enriched and 50% T  cell-enriched spleen 
cells produced the optimal antibody response. 
To assess the need for macrophages, spleen cell preparations were filtered through 
columns of Sephadex  G-10 before stimulation with Fc peptide. The  results reveal that 
Sephadex  G-10  filtration had  no effect on the level of polyclonal  antibody  produced 
(Fig.  4).  However,  as previously reported  (10,  1 i), G-10 filtration severely diminished 
the polyclonal  antibody  response induced  by Fc. 
Augmentation  of ln  Vitro and In  Vivo Humoral Immune Responses.  To study whether  the 
Fc peptide has the capacity to act  as an adjuvant,  it was added  to the in vitro spleen MORGAN  ET  AL.  951 
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Fz~.  4.  The requirement for macrophages in the Fc-peptide-induced murine polyclonal antibody 
response was assessed by Sephadex G-10 filtration of the spleen cells.  Cultures received either 7.5 
×  10  -5/~mol (0.17 btg) Fc peptide/ml or 1 ×  10  -n/xmol (166 #g) Fc/ml. 
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F=~.  5.  The  ability  of Fc  peptide  to  augment  the  murine in  vitro  anti-SRBC  was assessed by 
culturing spleen cells with Fc peptide and 0,1  ml of a  1% suspension of SRBC. 
cell cultures containing SRBC and the responses were measured. The data presented 
in  Fig.  5 show that the addition  of Fc peptide to murine spleen cell cultures  along 
with  low  doses  of  antigen  results  in  a  significant  augmentation  of the  response. 
Maximal enhancement  (4-5-fold) occurred when 0.03/.tg Fc peptide/ml was used in 
culture.  In addition  to the effects of Fc peptide on the murine in vitro response, the 
primary  human  anti-SRBC  response  was  analyzed.  Co-culture  of SRBC  and  Fc 
peptide  in  PBL  cultures  produced  an  enhanced  (5-6-fold)  anti-SRBC  response  as 
compared with cultures receiving only SRBC (Fig. 6). To further explore the adjuvant 
properties of the Fc peptide in vivo, mice were injected with peptide and SRBC and 952  LYMPIIOCYTE  ACTIVATION BY  SYNTItETIC  Fc  PEPTIDES 
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lqc,  6.  The ability of Fc peptide to augment the human in vitro anti-SRBC response was assessed 
by culturing human  PBL with  1.3 x  10 "~ btmol (0.03 btg) Fc peptide/ml and  I X  I0  -~ SRBC/ml. 
The response was measured on day 11 ofcuhure. 
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Fro.  7.  The ability of Fc peptide to  augment  the in  vivo anti-SRBC response  was  assessed by 
injecting mice with increasing  amounts of peptide and a constant amount of SRBC (0.1 ml of 1% 
suspension  of SRBC). The response was measured on day 5. 
the antibody response was measured.  The results indicate that  in vivo administration 
of the Fc peptide produces  a  significant augmentation  (5-6-fold)  of the primary anti- 
SRBC  response  (Fig.  7).  Optimal  stimulation  was  observed  when  25/*g  Fc  peptide 
per mouse was given intravenously.  The results in Fig. 8  were obtained when antigen 
and  peptide were both  injected on  day 0. 
Augmentation of In  Vitro T  Cell-mediated Proliferative Responses.  In addition  to  poten- 
tiating humoral immune  responses  (13,  14), Fc fragments have been shown to enhance 
murine  (15,  16)  and  human  (27)  T  cell-mediated responses.  To ascertain  whether the 
synthetic  Fc  peptide  maintained  this  capacity,  the  tetanus  toxoid-induced  T  cell 
proliferative response  was examined.  Stimulation  of human  PBL with tetanus  toxoid 
in  the presence  of Fc peptide  resulted  in  a  pronounced  enhancement  of the prolifer- MORGAN  ET  AL.  953 
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FIG.  8.  The ability of Fc peptide to augment NK cell activity. Mice were injected with 100/~g Fc 
peptide and their spleens were used as the source of NK cells 5 d  later. NK activity was measured 
by the ability of spleen cells to lyse 51Cr-labeled  Yae-1  target cells in a  4h assay, a.a., amino acid; 
E/T ratio, effector/target cell ratio; S.R., specific release• 
TABLE  II 
Ability of the 23-Amino Acid Peptide to Augment Tetanus Toxoid-induced 
Proliferation in Human PBL Cultures 
Tetanus 
Cells  toxoid  23 Peptide  [3H]Thymidine +_- SE 
(3/tg/ml)  (0.017/tg/ml) 
+  --  --  5,133 ±  2,069 
+  +  --  41,770--+  372 
+  +  +  101,730 --+ 320 
+  --  +  5,911  +-- 1,391 
ative response  (Table II). These results indicate  that  Fc peptide,  like Fc fragments, 
can potentiate both humoral and T  cell-mediated immune responses. 
Augmentation  of NK Responses.  Because in vivo administration of Fc fragments and 
synthetic  Fc  peptide  results  in  the  potentiation  of immune  responses,  experiments 
were  conducted  to  assess  whether  Fc  peptide  was  capable  of enhancing  NK  cell 
activity. As shown in Fig. 8, spleen cells from mice receiving Fc peptide were superior 
in their ability to lyse the NK-sensitive Yac-1 cell compared with those from untreated 
control mice. 
Discussion 
A  synthetic 23-amino acid peptide derived from the CH3 domain of human IgGt 
was  found  to  be a  potent  adjuvant  as well  as being  a  polyclonal  activator.  These 
responses are reminiscent of the immunoregulatory activities that have been described 
for Fc fragments (7-11), AHGG (12), and immune complexes (2, 7). 
The synthetic Fc peptide, on a  mole per mole basis, is more potent than native Fc 
fragments  in  inducing  polyclonal  antibody  production  and  potentiating  immune 954  LYMPHOCYTE ACTIVATION BY SYNTHETIC Fc PEPTIDES 
responses. The reason for this difference is unknown and a matter of speculation. Two 
possibilities that could account for the gain in activity are:  (a)  that Fc peptide has a 
higher affinity for receptors on lymphocytes, and (b) that a portion of the Fc molecule 
responsible  for  suppressing  immune  responses  is  not  associated  with  the  synthetic 
peptide. 
Accessory  T  cells  are  required  to  generate  the  Fc  peptide-induced  polyclonal 
antibody response.  This finding is identical  to what  is observed when Fc fragments 
are  used.  The role of the  T  cell  in  the  Fc  fragment-mediated polyclonal  antibody 
response is  the production  of a  soluble T  cell-replacing factor (TRF),  FcTRF  (26). 
Incubation of Fc fragments with Lyt-l+2  -  T  cells results in the secretion of FcTRF, 
which acts directly on the B cells, inducing them to differentiate to plasma cells and 
secrete  antibody  (27).  The  generation  of  polyclonal  antibody  by  Fc  peptide  is 
independent of macrophages. These results are in contrast to Fc fragment stimulation 
of murine and human lymphocytes (10,  11). Fc peptide behaves in a  fashion similar 
to Fc subfragments (10)  and plasmin-derived fragments  (7).  The role of the macro- 
phage is to enzymatically digest  the Fc fragment into biologically active  14-19,000- 
tool  wt  Fc subfragments that  are responsible for inducing  the  polyclonal antibody 
response (8-11).  Likewise, the plasmin fragment can stimulate lymphocytes without 
macrophage  processing  (7).  Both  Fc  subfragment  and  plasmin  Fc  are  capable  of 
inducing  B  cell  proliferation  (7),  which  contrasts with  the results obtained with  Fc 
peptide.  One possibility for this finding  is that  B cell proliferation requires  another 
portion of the CH3 domain. Alternatively, a portion of the CH3 domain in conjunction 
with this peptide is required  for proliferation. 
The immunomodulatory ability of the Fc fragment apparently lies in the Fc peptide 
since  this  peptide  has  the  capacity  to  enhance  both  humoral  and  cell-mediated 
immune  responses.  Injection  of Fc  peptide  along  with  antigen  or  the  addition  of 
peptide with antigen to in vitro cultures produces a pronounced augmentation of the 
specific antibody response. As described for the Fc fragment-induced adjuvant effect, 
the dose of antigen  used is critical.  Fc peptide can induce the greatest enhancement 
when suboptimal antigen doses are used. In addition to Fc fragments and Fc peptide, 
antigen  concentration  has been shown  to play a  critical role in  the adjuvanticity of 
other  agents  (28).  In  addition  to  potentiating  antibody  responses,  Fc  peptide  can 
enhance  antigen-induced  T  cell  proliferation.  We  have previously shown  that  the 
addition  of Fc fragments to in vitro human PBL cultures enhances the proliferative 
response to tetanus toxoid (17). 
Fc peptide can also modulate immune cytolysis mediated by NK cells.  Intravenous 
injection of Fc peptide renders the spleen cells of C57BL/6 mice more reactive to the 
NK-sensitive Yac-1 cell line. In vivo and in vitro administration of agents that induce 
an increase in interferon also enhance NK-mediated lysis (29).  It has been postulated 
that  the enhancement  of NK activity by interferon-inducing agents occurs through 
an increase in the lytic potential of effector ceils as opposed to clonal expansion. The 
mechanism  by  which  Fc  peptide  augments  NK  lytic  activity  is  unknown.  Thus, 
experiments are currently in progress to determine if Fc peptide induces an increase 
in interferon levels. 
The observation that a synthetic peptide derived from the CH3 domain of human 
Ig  can  modulate  homologous  and  heterologous  immune  responses  opens  up  the 
possibility of using the synthetic Fc peptide as a potential human adjuvant. An ideal MORGAN ET AL.  955 
adjuvant  would  be  a  nonimmunogenic  substance  that  could  potentiate  immune 
reactivity and yet not produce nonspecific inflammatory reactions. 
Summary 
A  synthetic 23-amino acid peptide derived from  the CHz domain of human  IgG1 
was found to be a  potent adjuvant as well as a  polyclonal activator. The Fc peptide 
was  found  to  enhance  human  and  murine  humoral,  and  T  cell-mediated immune 
responses. Moreover, in vivo administration of Fc peptide enhanced murine natural 
killer cell activity. The synthetic Fc peptide was found to be more potent, on a  molar 
basis,  than  native  Fc  fragments  in  inducing  polyclonal  antibody  production  and 
potentiating immune responses. 
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